You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts. Also inhibits growth of brain metastases in mouse model of non-small cell lung cancer.
View information regarding the usage of Iressa for non-clinical studies.
Sold for research purposes only under agreement from AstraZeneca
Iressa is also offered as part of the Tocriscreen Plus, Tocriscreen Kinase Inhibitor Toolbox I and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 446.9. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.24 mL||11.19 mL||22.38 mL|
|5 mM||0.45 mL||2.24 mL||4.48 mL|
|10 mM||0.22 mL||1.12 mL||2.24 mL|
|50 mM||0.04 mL||0.22 mL||0.45 mL|
References are publications that support the biological activity of the product.
Ciardiello et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res. 6 2053 PMID: 10815932
Baselga et al (2000) ZD1839 ('Iressa'), as an anticancer agent. Drugs 60 33 PMID: 11129170
McKillop et al (2005) Tumor penetration of gefi. (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 4 641 PMID: 15827338
Tan et al (2017) Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlo. in a nude mouse model. Oncotarget. 8 98771 PMID: 29228726
If you know of a relevant reference for Iressa, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Iressa, Iressa supplier, Orally, active, selective, EGFR, inhibitors, inhibits, Epidermal, Growth, Factors, Receptors, ErbB, Her, Receptor, Tyrosine, Kinases, RTKs, AstraZeneca, ZD1839, chemotherapeutics, Gefitinib, ZD, 1839, 3000, Tocris Bioscience
19 Citations for Iressa
Citations are publications that use Tocris products. Selected citations for Iressa include:
Li et al (2015) MetF. attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget 6 43605 PMID: 26497205
Curran et al (2015) Architecture of Chimeric Spheroids Controls Drug Transport. Cancer Microenviron 8 101 PMID: 26239082
Lindholm et al (2015) Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB Activity. J Clin Cell Immunol 6 PMID: 26317041
Moody et al (2014) SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner. Mol Cancer Res 100 25 PMID: 24496038
Joannes et al (2014) Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells. J Biol Chem 12 775 PMID: 24464917
Wang et al (2015) Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefi. Oncotarget 33 526 PMID: 25501339
Bill et al (2015) ANO1 interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. PLoS One 6 9173 PMID: 25823819
Kleczko et al (2015) An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. Life Sci 10 e0123600 PMID: 25946135
Qawasmi et al (2014) Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging. Front Pharmacol 5 257 PMID: 25484865
Kurimoto et al (2016) Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Oncol Rep 48 1825 PMID: 26984042
Li et al (2014) MetF. sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 20 2714 PMID: 24644001
Sakurai et al (2014) Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS One 9 e100124 PMID: 24971999
McMellen et al (2010) Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery 148 364 PMID: 20471049
Zhu et al (2016) Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer. Med Sci Monit 22 1435 PMID: 27125283
Bichsel et al (2013) Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS One 8 e69368 PMID: 23894460
Edris et al (2012) Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma 2012 805614 PMID: 22919280
Oda et al (2012) Stathmin is involved in the cooperative effect of zoled. acid and gefi. on bone homing breast cancer cells in vitro. J Bone Oncol 1 40 PMID: 26909254
Kitazono et al (2013) Effect of MetF. on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol 43 1846 PMID: 24100792
Moody et al (2015) CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells. J Mol Neurosci 56 663 PMID: 25761747
Do you know of a great paper that uses Iressa from Tocris? Please let us know.
Reviews for Iressa
There are currently no reviews for this product. Be the first to review Iressa and earn rewards!
Have you used Iressa?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.